Catalog Products » IL-17B hFc Chimera, Human
Manual
Manual
COAs

IL-17B hFc Chimera, Human

IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.
$430.00
Z05445-100

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-17B (Gln21-Phe180)
Accession # Q9UHF5		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.91 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

IL-17B HFc Chimera, Human

Immobilized IL-17B hFc Chimera, Human, hFc Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 20.7ng/ml determined by ELISA. »

IL-17B HFc Chimera, Human

The purity of IL-17B hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

IL-17B HFc Chimera, Human

IL-17B hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.
Synonyms IL17B; Interleukin-17B
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.